^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NEFH mutation

    i
    Other names: NEFH, Neurofilament Heavy, Neurofilament Heavy Polypeptide, Neurofilament, Heavy Polypeptide 200kDa, Neurofilament Triplet H Protein, 200 KDa Neurofilament Protein, NFH, KIAA0845, CMT2CC
    Entrez ID:
    380684
    almost2years
    Treatments and whole exon sequencing of a case with multiple primary lung cancer. (PubMed, J Cardiothorac Surg)
    This report showed an essential role in genomic detection and selecting the appropriate treatment of sMPLC. Surgery remains the primary treatment strategy for this type of disease, and the occurrence and development of sMPLC need more in-depth research.
    Journal
    |
    NEFH (Neurofilament Heavy)
    |
    NEFH mutation
    3years
    Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer. (PubMed, Oncoimmunology)
    Finally, the immune-associated score generated by hub genes was positively correlated with immune infiltration, immune activation, and a favorable prognosis. In conclusion, the dynamic changes in the TIM provide clues to drug selection and timing for TKI-immunotherapy combinations.
    Journal • Tumor Mutational Burden • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • NEFH (Neurofilament Heavy)
    |
    TP53 mutation • EGFR mutation • ALK positive • ALK rearrangement • EGFR rearrangement • NEFH mutation